S&P 500:  2,809.55  +11.12 (+0.40%)
DOW:  25,119.89  +55.53 (+0.22%)
NASDAQ:  7,855.12  +49.40 (+0.63%)

NASDAQ:VXRT - Vaxart News Headlines

Sign in or create an account to add this stock to your watchlist.
Get Started
$3.23 +0.11 (+3.53 %)
(As of 07/17/2018 04:00 PM ET)
Previous Close$3.12
Today's Range$3.05 - $3.23
52-Week Range$2.76 - $11.88
Volume8,671 shs
Average Volume68,384 shs
Market Capitalization$22.57 million
P/E RatioN/A
Dividend YieldN/A
Beta0.12

Headlines

Vaxart (NASDAQ VXRT) News Headlines

Source:
DateHeadline
Vaxart Announces Publication of the Phase 1 Results of its Oral Norovirus Tablet Vaccine in Journal of Clinical Investigation InsightVaxart Announces Publication of the Phase 1 Results of its Oral Norovirus Tablet Vaccine in Journal of Clinical Investigation Insight
finance.yahoo.com - July 12 at 10:04 AM
Reviewing Gilead Sciences (GILD) & Vaxart (VXRT)Reviewing Gilead Sciences (GILD) & Vaxart (VXRT)
www.americanbankingnews.com - July 9 at 8:08 PM
Oral RSV Vaccine - Preclinical Data Published in VaccineOral RSV Vaccine - Preclinical Data Published in Vaccine
finance.yahoo.com - June 27 at 9:42 AM
Genocea Biosciences (GNCA) versus Vaxart (VXRT) Head-To-Head SurveyGenocea Biosciences (GNCA) versus Vaxart (VXRT) Head-To-Head Survey
www.americanbankingnews.com - June 21 at 3:32 PM
Vaxart (VXRT) Director Purchases $17,000.00 in StockVaxart (VXRT) Director Purchases $17,000.00 in Stock
www.americanbankingnews.com - June 8 at 8:40 PM
Vaxart Reports Topline Results from Phase 2 Trial of Teslexivir™ for the Treatment of CondylomaVaxart Reports Topline Results from Phase 2 Trial of Teslexivir™ for the Treatment of Condyloma
finance.yahoo.com - June 4 at 8:53 AM
Financial Contrast: Vaxart (VXRT) versus Arsanis (ASNS)Financial Contrast: Vaxart (VXRT) versus Arsanis (ASNS)
www.americanbankingnews.com - June 2 at 11:34 AM
Vaxart to Present at ASM Microbe 2018Vaxart to Present at ASM Microbe 2018
finance.yahoo.com - June 1 at 8:57 AM
Vaxart to Present at the Jefferies 2018 Global Healthcare ConferenceVaxart to Present at the Jefferies 2018 Global Healthcare Conference
finance.yahoo.com - June 1 at 8:57 AM
Was Vaxart Inc’s (NASDAQ:VXRT) Earnings Growth Better Than The Industry’s?Was Vaxart Inc’s (NASDAQ:VXRT) Earnings Growth Better Than The Industry’s?
finance.yahoo.com - May 31 at 3:23 PM
Vaxart (VXRT) Issues Quarterly Earnings ResultsVaxart (VXRT) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 16 at 10:52 AM
Vaxart Announces First Quarter 2018 Financial Results and Corporate UpdateVaxart Announces First Quarter 2018 Financial Results and Corporate Update
finance.yahoo.com - May 16 at 8:22 AM
Vaxart Announces $5 Million Inavir® Revenue MilestoneVaxart Announces $5 Million Inavir® Revenue Milestone
finance.yahoo.com - April 20 at 3:21 PM
Vaxart Appoints Brant Biehn as Senior Vice President, Commercial OperationsVaxart Appoints Brant Biehn as Senior Vice President, Commercial Operations
finance.yahoo.com - April 19 at 3:22 PM
Vaxart to Present at Two Upcoming Medical MeetingsVaxart to Present at Two Upcoming Medical Meetings
finance.yahoo.com - April 17 at 7:25 AM
Vaxart Announces Oral Presentation of Clinical Data from Oral Influenza Vaccine Program at the World Vaccine CongressVaxart Announces Oral Presentation of Clinical Data from Oral Influenza Vaccine Program at the World Vaccine Congress
finance.yahoo.com - April 3 at 6:54 AM
Vaxart (VXRT) Receives Hold Rating from HC WainwrightVaxart (VXRT) Receives Hold Rating from HC Wainwright
www.americanbankingnews.com - April 2 at 6:59 PM
Vaxart (VXRT) Stock Rating Upgraded by ValuEngineVaxart (VXRT) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - March 25 at 8:45 PM
Who Really Owns Vaxart Inc (NASDAQ:VXRT)?Who Really Owns Vaxart Inc (NASDAQ:VXRT)?
finance.yahoo.com - March 22 at 3:18 PM
Analyzing Vaxart (VXRT) and Its RivalsAnalyzing Vaxart (VXRT) and Its Rivals
www.americanbankingnews.com - March 16 at 11:14 AM
Zacks: Vaxart Inc (VXRT) Given Consensus Rating of "Hold" by BrokeragesZacks: Vaxart Inc (VXRT) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 13 at 9:26 PM
Vaxart (VXRT) vs. The Competition Head-To-Head AnalysisVaxart (VXRT) vs. The Competition Head-To-Head Analysis
www.americanbankingnews.com - March 10 at 7:16 PM
Vaxart Expands Intellectual Property Portfolio With U.S. Patent AllowanceVaxart Expands Intellectual Property Portfolio With U.S. Patent Allowance
finance.yahoo.com - March 7 at 3:18 PM
Vaxart to Present Clinical Data From Oral Norovirus Vaccine Program at International Congress on Infectious DiseasesVaxart to Present Clinical Data From Oral Norovirus Vaccine Program at International Congress on Infectious Diseases
finance.yahoo.com - March 2 at 3:18 PM
Vaxart (VXRT) & Its Competitors Financial ContrastVaxart (VXRT) & Its Competitors Financial Contrast
www.americanbankingnews.com - February 27 at 5:14 AM
Analyzing Proteostasis Therapeutics (PTI) & Vaxart (VXRT)Analyzing Proteostasis Therapeutics (PTI) & Vaxart (VXRT)
www.americanbankingnews.com - February 22 at 12:42 PM
Zacks: Vaxart Inc (VXRT) Given Average Recommendation of "Hold" by AnalystsZacks: Vaxart Inc (VXRT) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - February 18 at 1:12 AM
This page was last updated on 7/17/2018 by MarketBeat.com Staff

Featured Article: Closed-End Mutual Funds
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.